Launch · Healthcare & Life Sciences

Cureous Labs launches turning system for hospitals

What they do

Cureous Labs designs medical devices for bedridden patients

It launched the Eturnal turning system, a retrofittable solution for hospitals

The company plans to expand into geriatric care and senior living centres

Cureous Labs is a medtech startup that designs medical devices for bedridden patients.
The company focuses on pressure injuries and patient transfer problems.
It launched the Eturnal turning system, a retrofittable solution for hospitals.
The product was tested with over 300 volunteers during development.
Cureous Labs provides on-site installation, training, and 24-hour problem response for customers.
The company currently delivers products across India.

The startup was founded by Asish Mohandas, who has a background in mechanical engineering and a Masters of Design at IIT Kanpur.
His healthcare pivot started with a thesis project on patient transfer.
He connected with clinicians at PGI during his thesis work.
He completed a Biodesign fellowship and received early grant funding.

Cureous Labs designs medical devices for bedridden patients.
Its focus areas are pressure injuries and patient transfer problems.
The design approach is jobs to be done, creating simple, reliable devices with no feature bloat.
The Eturnal turning system is a retrofittable solution for hospitals.
The company offers on-site installation, training, and 24-hour problem response.
Products are currently delivered across India.

The company plans to target geriatric care, senior living centres, assisted-living facilities, and hospitals.
Future plans include using AI, connected devices, and digital healthcare for smarter monitoring and predictive maintenance.

Product: based medical technology startup
Customers: Hospitals, rehabilitation centres, and home care providers
How it makes money: Develops and sells automated patient repositioning systems and related care products
What sets it apart: Retrofittable automatic repositioning system priced at about one-fifth of international alternatives